Company intelligence / Profile preview
PTC Therapeutics, Inc.
- Ownership
- Public · PTCT
- Employees
- ~5000
- Development stage
- Commercial
Overview
PTC Therapeutics has multiple approved products including Translarna for nonsense mutation Duchenne muscular dystrophy, Emflaza for Duchenne muscular dystrophy, Kebilidi/Upstaza (gene therapy) for AADC deficiency, and Evrysdi for spinal muscular atrophy. The company recently received a positive CHMP opinion for Sephience (sepiapterin) for PKU treatment and submitted a new drug application for vatiquinone to treat Friedreich ataxia.
- Therapeutic areas
- OncologyRare DiseasesNeurologyMetabolic Disorders
- Modalities
- Small moleculesGene therapySplicing modifiers
- Industry
- Biotech
Drug pipeline
22 assets21 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $5.6B
- Total revenue
- $360.5M
- Enterprise value
- $4.1B
Beyond the preview
Go deeper on PTC Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTC Therapeutics, Inc..